Suramin for Recluse Spider Bites

隐士蜘蛛叮咬的苏拉明：开发出第一个蜘蛛叮咬的生物技术公司SpiderTek 诊断性测试，建议使用苏拉明治疗由直立棘突咬伤引起的咬伤。 治疗非洲昏睡病的百年疗法。美国中南部8000万人口分享 隐居蜘蛛的家园。据估计，每年有3万人遭受隐蔽的蜘蛛叮咬，这种咬伤可能 导致疼痛，慢慢愈合伤口。每年有数百名患者发生溶血，这可能是 严重，特别是在儿童和老年人中。美国的治疗仅限于支持性治疗 措施。现在有了准确的诊断，下一步是开发有效的治疗方法。我们 根据苏拉明分子与磷脂酶D结合的发现，提出治疗方案， 隐居蜘蛛毒液中的活性成分。 这项拟议研究的总体目标是为这些蜘蛛咬伤开发一种优化的治疗方法。阶段 我将确定苏拉明治疗粘骨症的治疗限制。首先，我们将确定范围 当我们改变苏拉明剂量时，体内有效剂量的变化。接下来，我们将确定生效的时间窗口 治疗--咬伤后多长时间进行治疗才有效？最后，我们将比较 苏拉明注射采用一种新的局部给药技术，使患者能够避免紧急情况 房间探访。建议的研究将为我们建议的苏拉明疗法提供基本的概念验证 并使我们能够在计划中的第二阶段研究中开发人体试验。 最后，我们的跨学科研究团队涉及私有的SpiderTek和 密苏里大学。这两个实体都位于密苏里州农村，那里的弯曲症发病率很高。 该团队具有多学科的专业知识，包括一名动物科学家，第一个基于酶联免疫吸附试验的开发者 牛的妊娠测试以及我们的蜘蛛咬伤诊断测试，这位皮肤科医生在 隐居蜘蛛叮咬，以及广为人知的局部配方开发商。上一次成功 将第一个蜘蛛咬伤测试推向市场的经验，以及与 在首席研究员和他的同事们的支持下，该团队处于执行拟议研究的独特地位。

Suramin for Recluse Spider Bites: SpiderTek, a biotechnology company that developed the first spider bite diagnostic test, proposes therapy for bites due to Loxoscelesthre erecclulseusspiade,r, using suramin, a century-old treatment for African sleeping sickness. A population of 80 million in the South-Central US shares homes with the recluse spider. Each year, an estimated 30,000 persons suffer recluse spider bites that can result in painful, slowly healing wounds. Hundreds of patients annually develop hemolysis, which can be severe, especially in children and older persons. Therapy in the United States is limited to supportive measures. With accurate diagnosis now available, the next step is to develop an effective treatment. We propose a therapeutic solution based on the discovery that the suramin molecule binds to phospholipase D, the active component in the recluse spider venom. The overall objective of the proposed research is to develop an optimized therapy for these spider bites. Phase I will determine the therapeutic constraints of suramin therapy in loxoscelism. First, we will determine the range of the effective in-vivo dose as we vary suramin dose. Next, we will determine the time window for effective treatment—how soon after the bite does treatment have to occur to be effective? Finally, we will compare suramin injection with a novel topical administration technique, which will enable patients to avoid emergency room visits. The proposed research will provide basic proof-of-concept for our proposed suramin therapy for loxoscelism and enable us to develop a human trial in planned Phase II research. Finally, our interdisciplinary research team involves collaboration between privately held SpiderTek and the University of Missouri. Both entities are located in rural Missouri, where the incidence of loxoscelism is high. The team features multidisciplinary expertise, including an animal scientist, developer of the first ELISA-based pregnancy test for cattle as well as our spider bite diagnostic test, a dermatologist with extensive experience in recluse spider bites, and a widely recognized developer of topical formulations. With previous successful experience in bringing the first spider bite test to market and with strong existing collaborations between the principal investigator and his colleagues, the team is uniquely positioned to perform the proposed research.